Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics Inc (PSTV)
NASDAQ:PSTV
Plus Therapeutics (PSTV) Stock Price & Analysis
538 Followers
PSTV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.97 - $3.21
Previous Close$1.87
Volume98.83K
Average Volume (3M)90.44K
Market Cap
$10.67M
Enterprise Value$11.21M
Total Cash (Recent Filing)$3.22M
Total Debt (Recent Filing)$3.76M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Aug 12, 2024EPS Estimate
-$0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.19
Shares Outstanding5,704,219
10 Day Avg. Volume46,946
30 Day Avg. Volume90,444
Standard Deviation0.25
R-Squared0.01
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)4.66
Price to Sales (P/S)2.09
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.12
Enterprise Value/Gross Profit2.28
Enterprise Value/Ebitda-0.98
Forecast
1Y Price Target
$19.00Price Target Upside916.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Plus Therapeutics News
PremiumCompany Announcements
Plus Therapeutics CMO Dr. LaFrance Resignation Announced
PremiumCompany Announcements
Plus Therapeutics Secures Loan to Terminate Debt and Regain FreedomBulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsThe P2b ReSPECT-GBM study is progressing, with a data update expected which could potentially showcase the effectiveness of the treatment.
Financial StabilityThe company has adequate funding, including a stock purchase agreement and a grant, to support its operations and research into the future.
Regulatory MilestoneRhenium (186Re) obisbemeda was granted orphan drug designation by the FDA for the treatment of breast cancer with leptomeningeal metastases, which may provide certain benefits and incentives.
Bears Say
EarningsRevenue was $1.2 million, compared with estimates of $1.3 – 1.6 million.
Estimates AdjustmentAdjusting 2023 estimates for revenue to $5 million, from $6 million, and for EPS to $(4.21) from $(5.04).
GuidanceManagement did not provide 2023 guidance, but current quarterly cash burn is approximately $4 million.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PSTV FAQ
What was Plus Therapeutics Inc’s price range in the past 12 months?
Plus Therapeutics Inc lowest stock price was $0.97 and its highest was $3.21 in the past 12 months.
What is Plus Therapeutics Inc’s market cap?
Currently, no data Available
When is Plus Therapeutics Inc’s upcoming earnings report date?
Plus Therapeutics Inc’s upcoming earnings report date is Aug 12, 2024 which is in 15 days.
How were Plus Therapeutics Inc’s earnings last quarter?
Plus Therapeutics Inc released its earnings results on May 15, 2024. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$1.09 by $0.34.
Is Plus Therapeutics Inc overvalued?
According to Wall Street analysts Plus Therapeutics Inc’s price is currently Undervalued.
Does Plus Therapeutics Inc pay dividends?
Plus Therapeutics Inc does not currently pay dividends.
What is Plus Therapeutics Inc’s EPS estimate?
Plus Therapeutics Inc’s EPS estimate is -$0.53.
How many shares outstanding does Plus Therapeutics Inc have?
Plus Therapeutics Inc has 5,704,219 shares outstanding.
What happened to Plus Therapeutics Inc’s price movement after its last earnings report?
Plus Therapeutics Inc reported an EPS of -$0.75 in its last earnings report, beating expectations of -$1.09. Following the earnings report the stock price went down -3.017%.
Which hedge fund is a major shareholder of Plus Therapeutics Inc?
Currently, no hedge funds are holding shares in PSTV
---
Plus Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (916.04% Upside)
$19.00 (916.04% Upside)
Insider Transactions
Bought Shares
Worth $98.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-64.06%
Trailing 12-Months
Company Description
Plus Therapeutics Inc
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and manufacturing scale up of complex and innovative treatments for patients battling cancer and other life-threatening diseases. The proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. The lead drug product candidate in pipeline, DocePLUS™, is being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, and other professionals. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.
---
PSTV Earnings Call
Q1 2024
0:00 / 0:00
---
PSTV Stock 12 Month Forecast
Average Price Target
$19.00
▲(916.04% Upside)
Technical Analysis
Best Analysts Covering PSTV
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-35.41%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -35.41% per trade.
---